Advanced Recurrent Ovarian Cancer Global Market Report 2025

The advanced recurrent ovarian cancer market size has grown strongly in recent years. It will grow from $2.5 billion in 2024 to $2.72 billion in 2025 at a compound annual growth rate (CAGR) of 8.7%. The growth during the historic period was driven by the increasing prevalence of ovarian cancer, limited treatment options for advanced stages, rising awareness of ovarian cancer symptoms, growing healthcare spending, and advancements in chemotherapy regimens.

The advanced recurrent ovarian cancer market size is expected to see strong growth in the next few years. It will grow to $3.75 billion in 2029 at a compound annual growth rate (CAGR) of 8.4%. The projected growth during the forecast period is driven by an increasing focus on personalized medicine, the expansion of targeted therapies and immunotherapies, rising investment in cancer research, improved healthcare access in emerging markets, and an aging population. Key trends include the use of artificial intelligence for early detection, the development of liquid biopsy technologies, the integration of biomarker-driven therapies, advancements in gene editing technologies, and the growing adoption of precision medicine.

The increasing emphasis on personalized medicine is expected to drive the growth of the advanced recurrent ovarian cancer market. Personalized medicine involves tailoring medical treatment to an individual’s genetic profile, lifestyle, and specific health conditions to provide the most effective and targeted therapy. The rise of personalized medicine is fueled by advancements in genomics, biotechnology, and data analytics, allowing for more precise identification of genetic variations and disease biomarkers. Advanced recurrent ovarian cancer contributes to the development of personalized medicine by emphasizing the need for customized treatment approaches that address specific genetic mutations and molecular characteristics of each patient’s tumor, thereby improving therapeutic outcomes and reducing recurrence rates. For example, in February 2024, the Personalized Medicine Coalition, a US-based organization advocating for personalized medicine adoption, reported that the U.S. Food and Drug Administration approved 16 new personalized treatments for rare disease patients, an increase from six in 2022. As a result, the growing focus on personalized medicine is fueling the expansion of the advanced recurrent ovarian cancer market.

Leading companies in the advanced recurrent ovarian cancer market are prioritizing the development of innovative treatments, such as antibody-drug conjugates, to enhance treatment precision, improve drug delivery to cancer cells, reduce off-target effects, and address resistance to traditional therapies. Antibody-drug conjugates (ADCs) are a form of targeted cancer therapy that combines a monoclonal antibody specific to cancer cells with a cytotoxic drug, ensuring precise drug delivery to tumor cells while minimizing harm to healthy tissues. For instance, in January 2024, RemeGen Co. Ltd., a China-based biopharmaceutical company, announced that its independently developed RC88, a mesothelin (MSLN)-targeting antibody-drug conjugate, received FDA Fast Track Designation for treating platinum-resistant recurrent epithelial ovarian cancer, fallopian tube cancer, and primary peritoneal cancers. This product integrates a recombinant humanized anti-MSLN monoclonal antibody with monomethyl auristatin E (MMAE), a potent microtubule inhibitor. The ADC technology facilitates the precise delivery of cytotoxic agents to tumor cells, enhancing therapeutic efficacy while minimizing systemic toxicity. RemeGen utilizes a proprietary bridging technology to optimize the connection between antibodies and drugs.

In February 2024, AbbVie Inc., a US-based pharmaceutical company, acquired ImmunoGen Inc. for an undisclosed amount. This acquisition aims to strengthen AbbVie’s oncology portfolio by incorporating ImmunoGen’s expertise in antibody-drug conjugates (ADCs) and its promising treatments for advanced cancers, including ovarian cancer. ImmunoGen Inc. is a US-based company specializing in the development of ADC therapies for cancer treatment.

Major players in the advanced recurrent ovarian cancer market are Pfizer Inc., Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Bristol Myers Squibb Company, AstraZeneca plc, Novartis International AG, GSK plc, Eli Lilly and Company, Amgen Inc., Regeneron Pharmaceuticals Inc., Genentech Inc., Exelixis Inc., Mirati Therapeutics Inc., Kite Pharma Inc., ImmunoGen Inc., Clovis Oncology Inc., Debiopharm International SA, Celsion Corporation.

North America was the largest region in the advanced recurrent ovarian cancer market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in advanced recurrent ovarian cancer report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the advanced recurrent ovarian cancer market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Advanced recurrent ovarian cancer is a form of ovarian cancer that has returned after initial treatment and has progressed beyond the ovaries. This condition is typically classified as stage III or IV, where the cancer may spread to nearby organs in the pelvis or abdomen and potentially metastasize to distant sites, such as the lungs.

The primary types of advanced recurrent ovarian cancer include epithelial ovarian cancer and non-epithelial ovarian cancer. Epithelial ovarian cancer originates in the epithelial cells lining the ovaries, which are responsible for producing eggs and hormones. Treatment options include targeted therapy, chemotherapy, surgery, radiation, and biological therapy. Patients fall into different age groups, including pediatric, young adults (18-39), middle-aged (40-59), and seniors (60+). These treatments are administered in various healthcare settings, such as hospitals, clinics, and pharmacies.

The advanced recurrent ovarian cancer market research report is one of a series of new reports that provides advanced recurrent ovarian cancer market statistics, including advanced recurrent ovarian cancer industry global market size, regional shares, competitors with an advanced recurrent ovarian cancer market share, detailed advanced recurrent ovarian cancer market segments, market trends and opportunities, and any further data you may need to thrive in the advanced recurrent ovarian cancer industry. This advanced recurrent ovarian cancer market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The advanced recurrent ovarian cancer market includes revenues earned by entities by providing services such as diagnostic services, treatment services, and supportive care services, and related products such as pharmaceutical drugs, diagnostic products, medical devices, and supportive care products. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.